TRASTUZUMAB IN BREAST, CANCER

Monoclonal antibodies, as a novel therapeutic modality, are currently in use and have an increasing significance in breast cancer, including both metastatic and adjuvant settings. Numerous studies have been performed to address their predictive and prognostic role in breast cancer. HER-2/neu, a proto-oncogene located on chromosome 17 is overexpressed in 20- 30% of breast cancer. HER-2/neu encodes the HER-2 which is an epidermal growth factor receptor protein. Trastuzumab is a recombinant monoclonal anti-body against HER-2 receptor protein and appears to be beneficial in targeted therapy of breast cancer.

Keywords: breast cancer, trastuzumab